Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.52 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.42 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.41 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6669514 | 0.79 | FGFR1 (0.61) | MAPK1FGFR1ALDH1A1TSHRKDM4E | |
| SCHEMBL2880089 | 0.73 | PRKD3 (0.42) | FGFR1ALDH1A1TP53KDM4EHPGD | |
| SCHEMBL13683022 | 0.73 | MAPK1 (0.50) | MAPK1HTTPOLBFGFR1ALDH1A1 | |
| SCHEMBL30524297 | 0.72 | HTT (0.62) | MAPK1HTTPOLBFGFR1MKNK1 | |
| SCHEMBL29947266 | 0.72 | KDM4E (0.49) | FGFR1ALDH1A1KDM4E | |
| SCHEMBL7596615 | 0.72 | MKNK1 (0.50) | MAPK1HTTPOLBFGFR1ALDH1A1 | |
| SCHEMBL15748197 | 0.71 | DRD2 (0.61) | TSHR | |
| SCHEMBL16756420 | 0.70 | MAPK1 (0.57) | MAPK1HTTPOLBFGFR1ALDH1A1 | |
| SCHEMBL21772160 | 0.68 | HTR2C (0.39) | MAPK1FGFR1ALDH1A1MKNK2KDM4E | |
| SCHEMBL3417306 | 0.68 | HTT (0.73) | HTTPOLBFGFR1ALDH1A1MKNK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8455471-B2 | Compositions of CHK1 inhibitors and cyclodextrin | ICOS CORPORATION (US) | 2013-06-04 | — | — | US | disclosed |
| US-8093244-B2 | Heteroaryl urea derivatives useful for inhibiting CHK1 | ICOS CORPORATION (US) | 2012-01-10 | — | — | US | disclosed |
| EP-2330105-A1 | Heteroaryl urea derivatives useful for inhibiting CHK1 | ICOS Corporation (US) | 2011-06-08 | — | — | EP | disclosed |
| EP-1869020-B1 | HETEROARYL UREA DERIVATIVES USEFUL FOR INHIBITING CHK1 | ICOS CORP (US) | 2010-12-01 | — | — | EP | disclosed |
| US-20100022512-A1 | COMPOSITIONS OF CHK1 INHIBITORS AND CYCLODEXTRIN | WISDOM WENDY A | 2010-01-28 | — | — | US | disclosed |
| US-7560462-B2 | Compounds useful for inhibiting CHK1 | ICOS CORPORATION (US) | 2009-07-14 | — | — | US | disclosed |
| US-20090143357-A1 | HETEROARYL UREA DERIVATIVES USEFUL FOR INHIBITING CHK1 | ICOS CORPORATION (US) | 2009-06-04 | — | — | US | disclosed |
| EP-2063879-A2 | COMPOSITIONS OF CHK1 INHIBITORS AND CYCLODEXTRIN | ICOS Corporation (US) | 2009-06-03 | — | — | EP | disclosed |
| US-7541367-B2 | 3-benzoimidazolyl-pyrazolopyridines useful in treating kinase disorders | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-06-02 | — | — | US | disclosed |
| US-20090048249-A1 | 3-benzoimidazolyl-pyrazolopyridines useful in treating kinase disorders | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-02-19 | — | — | US | disclosed |
| WO-2008067027-A2 | COMPOSITIONS OF CHKL INHIBITORS AND CYCLODEXTRIN | ICOS CORPORATION (US) | 2008-06-05 | — | — | WO | disclosed |
| EP-1869020-A1 | HETEROARYL UREA DERIVATIVES USEFUL FOR INHIBITING CHKl | ICOS Corporation (US) | 2007-12-26 | — | — | EP | disclosed |
| EP-1778648-A2 | COMPOUNDS USEFUL FOR INHIBITING CHK1 | ICOS Corporation (US) | 2007-05-02 | — | — | EP | disclosed |
| EP-1768977-A2 | COMPOUNDS USEFUL FOR INHIBITING CHK1 | ICOS Corporation (US) | 2007-04-04 | — | — | EP | disclosed |
| EP-1765808-A1 | BISARYLUREA DERIVATIVES USEFUL FOR INHIBITING CHK1 | ICOS Corporation (US) | 2007-03-28 | — | — | EP | disclosed |
| WO-2006130673-A1 | 3-BENZOIMIDAZOLYL-PYRAZOLOPYRIDINES USEFUL IN TREATING KINASE DISORDERS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-12-07 | — | — | WO | disclosed |
| WO-2006105262-A1 | HETEROARYL UREA DERIVATIVES USEFUL FOR INHIBITING CHKl | ICOS CORPORATION (US) | 2006-10-05 | — | — | WO | disclosed |
| WO-2006021002-A2 | COMPOUNDS USEFUL FOR INHIBITING CHK1 | ICOS CORPORATION (US) | 2006-02-23 | — | — | WO | disclosed |
| WO-2006014359-A2 | COMPOUNDS USEFUL FOR INHIBITING CHK1 | ICOS CORPORATION (US) | 2006-02-09 | — | — | WO | disclosed |
| WO-2006012308-A1 | BISARYLUREA DERIVATIVES USEFUL FOR INHIBITING CHK1 | ICOS CORPORATION (US) | 2006-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048249-A1 | 3-benzoimidazolyl-pyrazolopyridines useful in treating kinase disorders | PRKDC, PRKACA, ABL1 | MAPK1 340/4885HTT 4161/4885POLB 2356/4885 |
| US-20090143357-A1 | HETEROARYL UREA DERIVATIVES USEFUL FOR INHIBITING CHK1 | CHEK1, CHEK2, PCNA | MAPK1 2909/4885HTT 2649/4885POLB 73/4885 |
| US-20100022512-A1 | COMPOSITIONS OF CHK1 INHIBITORS AND CYCLODEXTRIN | CHEK1, CHEK2, DDB1 | MAPK1 1564/4885HTT 4429/4885POLB 193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.